Ansofaxine
Clinical data | |
---|---|
Other names | LY03005; LPM570065; 4-Methylbenzoate desvenlafaxine |
Routes of administration | By mouth |
Identifiers | |
| |
JSmol) | |
| |
|
Toludesvenlafaxine, also formerly known as ansofaxine and sold under the brand name Ruoxinlin, is an antidepressant which is approved for the treatment of major depressive disorder in China.[1] It is also under development for use in other countries like the United States.[1] It is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) and was developed by Luye Pharma Group.[1][2][3][4]
Toludesvenlafaxine is described as an SNDRI and
As of July 2018, toludesvenlafaxine is in preregistration for the treatment of depression in the United States, the European Union, and Japan.[1] As of January 2023, it is also in phase 3 clinical trials for the treatment of generalized anxiety disorder.[1] In March 2020, the United States Food and Drug Administration accepted Luye Pharma's New Drug Application for toludesvenlafaxine, which remains under review.[1][5] In November 2022, toludesvenlafaxine was approved for the treatment of depression in China under the brand name Ruoxinlin.[6][7]
References
- ^ a b c d e f "Toludesvenlafaxine extended release - Luye Pharma". AdisInsight. Springer Nature Switzerland AG.
- ^ PMID 24614602.
- PMID 25813654.
- ^ Completion of Phase 1 Clinical Studies of Ansofaxine Hydrochloride Extended Release Tablets (LY03005) in the U.S.
- ^ "Luye Pharma Releases Top-Line Results from a Phase II Clinical Trial of Its New Antidepressant Ansofaxine Hydrochloride Extended-Release Tablets". BioSpace. Retrieved 2022-02-08.
- ^ "Luye Pharma's Class 1 Innovative Antidepressant Ruoxinlin® Approved for Launch in China - Press Releases - Luye Pharma Group". www.luye.cn. Retrieved 2022-12-04.
- ^ "R&D - Luye Pharma Group". www.luye.cn. Retrieved 2022-10-06.